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Policies to adequately respond to the rise in multimorbidity have top-priority. To understand
the actual burden of multimorbidity, this study aimed to: 1) estimate the trend in prevalence
of multimorbidity in the Netherlands, 2) study the association between multimorbidity and
physical and mental health outcomes and healthcare cost, and 3) investigate how the asso-
ciation between multimorbidity and health outcomes interacts with socio-economic status
(SES).
Methods
Prevalence estimates were obtained from a nationally representative pharmacy database
over 2007–2016. Impact on costs was estimated in a fixed effect regression model on claims
data over 2009–2015. Data on physical and mental health and SES were obtained from the
National Health Survey in 2017, in which the Katz-10 was used to measure limitations in
activities of daily living (ADL) and the Mental Health Inventory (MHI) to measure mental
health. SES was approximated by the level of education. Generalized linear models (2-part
models for ADL) were used to analyze the health data. In all models an indicator variable for
the presence or absence of multimorbidity was included or a categorical variable for the
number of chronic conditions. Interactions terms of multimorbidity and educational level
were added into the previously mentioned models.
Results
Over the past ten years, there was an increase of 1.6%-point in the percentage of people
with multimorbidity. The percentage of people with three or more conditions increased with
+2.1%-point. People with multimorbidity had considerably worse physical and mental health
outcomes than people without multimorbidity. For the ADL, the impact of multimorbidity was
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three times greater in the lowest educational level than in the highest educational level. For
the MHI, the impact of multimorbidity was two times greater in the lowest than in the highest
educational level. Each additional chronic condition was associated with a greater worsen-
ing in health outcomes. Similarly, for costs, where there was no evidence of a diminishing
impact of additional conditions either. In patients with multimorbidity total healthcare costs
were on average €874 higher than in patients with a single morbidity.
Conclusion
The impact of multimorbidity on health and costs seems to be greater in the sicker and lower
educated population.
Introduction
Multimorbidity, defined as two or more chronic conditions occurring in one person at the
same time, is an increasing problem, particularly in countries with a rapidly ageing population
[1, 2]. The number of patients with multimorbidity in Europe is around 50 million and is
increasing every year [2]. Compared to patients without multimorbidity, those with multimor-
bidity have a higher mortality rate [3, 4], a higher rate of polypharmacy [5], worse health-
related quality of life (HRQoL) [6–8], higher healthcare costs [9–11], and more productivity
loss [12] after adjustment of age and other confounders. Moreover, they are disproportionately
affected by the fragmentation and the single-disease orientation of the health and social care
system [13]. The need for investments in potential solutions such as whole-system, person-
centred integrated care is widely recognized. To justify and plan such investments and ensure
access for all people with multimorbidity across the layers of the population, it is crucial to
have accurate data on the (change in) prevalence of multimorbidity and its impact on physical
and mental health, and costs.
Prevalence estimates of multimorbidity and their increase with age and over time vary con-
siderably due to differences in definitions of multimorbidity and sources of data used [14–18].
The most up to date prevalence estimate for the Netherlands was 31.8% in 2018 [19], which
was based on a general practitioner (GP) registry. An estimate of (change in) prevalence that is
based on a national database representing the entire Dutch population is lacking.
Several studies have investigated the association between multimorbidity and health out-
comes, both physical [6–8, 20–22], and mental [6, 8, 23, 24], but many were either small [7,
21], not representative for the entire country [8, 23], focused on a specific subgroup like elderly
[6, 7, 21, 22], or focused on a limited number of chronic diseases [24–26]. There are many
papers on socio-economic inequalities in health, which clearly demonstrate that lower SES is
associated with greater mortality [27, 28], higher prevalence of multimorbidity [29] and worse
health outcomes [30] To the best of our knowledge, none of them investigated how the associa-
tion between multimorbidity and health varies by SES.
The impact of multimorbidity on costs varies by healthcare system and methods used to
derive costs [10, 31]. In a recent review study, the ratios of multimorbidity costs to non-multi-
morbidity costs ranged from 2–16 [32]. Most of the studies in this review were cross-sectional
and half of them were based on U.S. data. There is no longitudinal study on the impact of mul-
timorbidity on healthcare costs in the Netherlands.
The aim of our study was to fill in the information gaps identified above. This study pro-
vides recent estimates of the prevalence of multimorbidity in the Netherlands and its change
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over time. Furthermore, we investigated the association between multimorbidity and physical
health, mental health and healthcare costs, using databases that are representative for the entire
country. In addition, we investigated how educational level interacts with the association
between multimorbidity and health.
Methods
We have used data from a nationally representative pharmacy database, claims database and a
health survey to estimate the change in prevalence of multimorbidity and the impact of multi-
morbidity on health and healthcare costs. All databases used in this study were provided by
Statistics Netherlands (CBS, Centraal Bureau voor de Statistiek), the national statistics office of
the Netherlands. The study population was the entire adult population (18 years old and over)
in the Netherlands. The prevalence estimation was based on data from 2006 to 2016, the asso-
ciation between multimorbidity and health outcomes was based on data from 2017, and the
estimated impact of multimorbidity on healthcare costs was based on panel data from 2009 to
2015.
Identification of chronic conditions and prevalence of multimorbidity
To estimate the prevalence, we used a longitudinal pharmacy database that contained data
from everyone in the Netherlands that received medication included in the basic health insur-
ance package, which is approximately 11 million adults (85% of total population) each year
[33]. In the Netherlands, every resident is mandatorily enrolled in basic health insurance. All
prescribed medicines covered by the basic insurance, including those prescribed by GP’s, to
hospital outpatients and patients in residential homes, are recorded in this dataset. The medi-
cation prescribed during in-patient hospital stays and over-the-counter medicines are not
included in the pharmacy database.
The individual-level prescriptions of medications are coded and categorized using the Ana-
tomical Therapeutic Chemical (ATC) classification system, up to the third level, which is the
pharmacological subgroup level [34]. We matched these ATC codes to a list of 21 chronic con-
ditions: acid-related disorders, bone diseases, cancer, cardiovascular diseases, dementia, diabe-
tes mellitus, epilepsy, glaucoma, hyperuricemia (gout), chronic viral infection, hyperlipidemia,
intestinal inflammatory diseases, iron deficiency anemia, migraines, pain, Parkinson’s disease,
psychological disorders, psychoses, respiratory illness, thyroid disorders, and tuberculosis. To
do so we used the Swiss classification by Huber et al. [35], which was an updated version of the
original Dutch classification by Lamers et al. [36], that was used in the risk equalization scheme
of the Dutch health insurance. Hence this classification was deemed suitable to be used in a
study addressing the entire adult population in the Netherlands.
In line with the WHO definition of multimorbidity, adults with two or more chronic condi-
tions in the same year were defined as having multimorbidity [37]. To avoid overestimating
the prevalence of chronic conditions, we only labeled a condition as chronic when medication
for a certain chronic disease was prescribed at least two years in a row. This continuity crite-
rium was used by previous studies [38, 39].
To estimate the prevalence of multimorbidity by gender and age, the pharmacy database
was linked to the municipal basic administration (GBA, Gemeentelijke Basis Administratie)
database from CBS, which contains demographic information (year of birth and gender) for
all residents in the Netherlands [40]. Data were linked by CBS, using a pseudonymized com-
mon ID that is unique for each individual. Information on annual size of the total population
in the Netherlands was extracted from StatLine [41].
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Health outcomes
To estimate the association between multimorbidity and health outcomes, which include phys-
ical and mental health outcomes, we used data from the Health Survey database [42]. This
database contains data from a nation-wide, cross-sectional, annual Health Survey on health
and the need for healthcare in the Netherlands, including self-reported physical and mental
health, and demographic information such as age, gender, and highest education level.
Approximately 15,000 participants across the country are sampled for the survey each year,
with a response rate of 63% in 2017 (approximately 9,500 respondents), from which we
selected all 7,741 respondents that were 18 years and older in the year 2017. The average age of
this dataset is 52.8 years old, 50.5% of the respondents are male (S3 Table). The sample is dis-
tributed evenly over all months of the year. First, persons are asked to participate via the inter-
net. Non-responders are re-approached to participate in a face-to-face interview by way of
Computer-Assisted Personal Interviewing. A correction is applied to control for differences
between the sample and the population. For this purpose, a weighting factor is used based on
sex, age, migration background, marital status, degree of urbanisation, province, household
size, income, wealth, and survey season. The background characteristics of the Health Survey
responders were proven by CBS to be similar to the general population in the Netherlands
[42].
Physical health was measured with the Katz-10. This is a validated questionnaire [43, 44],
which consists of ten questions asking respondents whether they need help with ADL such as
eating, dressing, personal hygiene, mobility in getting up from bed, dressing, transferring, and
use of the toilet [45]. The five response options ranged from no difficulty to not even with the
help of others. Participants under 54 years only had to answer three of these ten questions, i.e.,
about their ability to get up from a chair, to get up from a bed and walk up a flight of stairs. For
both age groups, responses were linearly transformed onto a scale from 0 (best) to 100 (worst)
[46].
Mental health was measured by the Mental Health Inventory 5 (MHI-5). This is a validated
questionnaire [47], which consists of five questions asking how much of the time during the
last four weeks the respondents had felt happy, calm and peaceful, nervous, downhearted and
blue, and so down in the dumps that nothing could cheer them up [48]. The six response
options ranged from none of the time to all of the time. Responses were linearly transformed
onto a scale from 0 (worst) to 100 (best) [49].
The Health Survey database also contains age, gender, and highest education level achieved,
which was classified into five levels, i.e. primary education; pre-vocational training; high school
or vocational training; higher education until Bachelor; and master/doctorate [50]. The multi-
morbidity status of the Health Survey respondents was obtained by linking to the prevalence
data (2016). In all the databases provided by CBS, each individual has one unique, encrypted
RIN code. This RIN code enable us to link several databases on individual level.
Healthcare costs
To estimate the impact of multimorbidity on healthcare expenditure, we used a database of
health insurance data, containing annual individual-level claims data from 2009 to 2015 [51].
Sixteen categories of costs are included, that cover all expenditures reimbursed by the compul-
sory basic health insurance in the Netherlands, including GP care, hospital care, dental care,
pharmaceuticals, other costs (e.g. paramedic, assistive device and birth care), and total costs.
Costs of GP care include the annual per capita registration fee, the consultation fees and other
costs incurred by the GP. Costs of hospital care include both inpatient and outpatient hospital
care. Pharmacy costs include all the costs of medicines, except for the ones administered
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during a hospital admission. From the health insurance database, we included only the adult
population (18 or older), which was around 2,450,000 each year in the period from 2009 to
2015 (17,048,049 observations for adults across these years in total).
As healthcare costs increase substantially in the year of death [52, 53], it was essential to
have mortality data to know whether an individual had died in a certain year. Mortality data
for all deceased Dutch residents were obtained from the National Mortality Database, which
includes the date and cause of death of all residents in the Netherlands. End-of-life costs were
defined as the healthcare expenditures during the year of death.
Statistical analyses
Prevalence. For each year from 2007 to 2016, the prevalence of multimorbidity was calcu-
lated as the number of adults with multimorbidity (in a certain age class) divided by the num-
ber of adults (in that age class) living in the Netherlands that year. We further classified
patients according to their number of chronic conditions (0, 1, 2, 3, 4, and 5 or more) and esti-
mated the prevalence of each class.
Health outcomes. To analyse the association between multimorbidity and ADL, we esti-
mated two-part models (2PM), because a large proportion of the people has a score of 0, indi-
cating no problems with their ADL [45]. This makes the conventional ordinary least squares
(OLS) inappropriate. In the first part of the 2PM, we used a logit model to estimate the proba-
bility of having an ADL score higher than 0, including morbidity status (0 for no morbidity, 1
for single morbidity, and 2 for multimorbidity), age, gender and educational level:




Where Pr (ADLi> 0|Xi) is the probability of ADL score to be positive with given age, gender,
multimorbidity status, and education level, α is the constant, and βi are parameters in the
model, which are age, gender, multimorbidity status and education level.
The second part of the 2PM estimated the ADL score among those with a non-zero score,
using a generalized linear model with a gamma distribution and log-link function, because the
data were skewed to the right. The choice of the model was driven by the Manning and Mul-
lahy algorithm [54]. Like in the first part, the model included morbidity status, age, gender and
educational level:
lnðEðADLiÞÞ ¼ aþ b � xi þ ε ð2Þ
Where ε stands for the error term. The results of the 2PM combined the probability estimated
in the first part and the ADL score estimated in the second part:
EðADLijxiÞ ¼ PrðADLi > 0jXiÞ � EðADLijxi; ADLi > 0Þ ð3Þ
To analyse the association between multimorbidity and MHI score, we estimated a general-
ized linear model with the same independent variables as above. Based on the Manning and
Mullahy algorithm [54], the identity link function and normal distribution were chosen in this
analysis.
MHIi ¼ aþ b � xi þ ε ð4Þ
To investigate whether the association between multimorbidity and ADL or MHI scores
differed by level of education, interaction variables of morbidity status and level of education
were added to the models above.
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Healthcare costs. We used fixed-effects regression models to estimate the associations
between multimorbidity and healthcare costs [55]. A major concern for observational studies
involving human behaviours is the presence of unmeasured potential confounding factors.
With the panel dataset that provided individual-level information, we addressed this concern
by the ‘within estimation’ of a fixed-effect model, which takes each individual as its own con-
trol and estimates the change in healthcare costs of each individual after the morbidity status
changed and cancels out those unmeasured, time-invariant confounding factors such as medi-
cal care-seeking behaviour [55].
In all models the three-level morbidity status (i.e., 0, 1 for single morbidity, 2 for multimor-
bidity (i.e., 2+)) was replaced by a six-level morbidity status (i.e., 0, 1, 2, 3, 4, and 5 or more) to
investigate the impact of the number of morbidities on health outcomes and costs. All analyses
were conducted using Stata 14 statistical software.
Results
Prevalence
The prevalence of multimorbidity in Dutch adults was 23.2% in 2007 and had increased to
24.7% in 2016 (S1 Table). This raise was primarily due to an increase in those aged over 69
(Fig 1). Compared to 2007, the prevalence has risen with 1.5% points. Over the past ten years,
there was a considerable increase in the proportion of people with three or more chronic con-
ditions (Fig 2).
Fig 1. Change in prevalence or multimorbidity by age groups compared to 2007.
https://doi.org/10.1371/journal.pone.0243275.g001
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According to the prevalence estimations in 2016, the prevalence of multimorbidity
increased sharply with age to 76.2% in the 80 years old or older.
Health outcomes
Table 1 shows the association between multimorbidity and health outcomes, both for physical
and mental health. The odds ratio of having a non-zero ADL score (i.e. having ADL problems)
was 3.8 (13.17/3.43) times higher for the multimorbidity group than for the single morbidity
group, after adjustment for differences in age, gender, and education level (Table 1). Among
those with a non-zero ADL score, the ADL score of those with multimorbidity was 2.2
(1.2�10.6–1.4�10.6) units worse than the ADL score of those with a single morbidity. Combin-
ing the results of both parts, the ADL score of the multimorbidity group was 3 units worse
than the ADL score of the single morbidity group. Table 1 also shows that, compared to the
non-morbidity group, the MHI score worsened by 1.7 units in the single morbidity group and
5 units in the multimorbidity group.
The regression results showing the association between multimorbidity and physical and
mental health outcomes across different education levels are reported in S2 Table. Fig 3 shows
the interaction between educational level and the impact of multimorbidity on ADL, and Fig 4
does so for the MHI. The lower the education level, the greater the difference in ADL score
and MHI score between multimorbidity and no morbidity. Compared to the non-morbidity
Fig 2. Change in prevalence of different numbers of chronic conditions compared to 2007.
https://doi.org/10.1371/journal.pone.0243275.g002
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group, the ADL score was 6.6 units worse in the group with the lowest educational level,
whereas it was only 2.3 units worse in the group with the highest educational level. Compared
to the non-morbidity group, the MHI score was 6.4 units worse in the group with the lowest
educational level, whereas it was only 3.5 units worse in the group with the highest educational
level.
Table 2 shows the association between the number of chronic conditions and the ADL and
MHI scores. The group with two chronic conditions had an ADL score that was 1.7 units (cal-
culated with Eq (3)) worse than the group with no chronic conditions, whereas the group with
five or more chronic conditions had and ADL score that was 10 units (calculated with Eq (3))
worse. The MHI score for the group with two chronic conditions was 3.4 units worse than that
of the group with no chronic conditions, whereas that of the group with five or more chronic
conditions was 8.7 units worse.
As the number of chronic conditions increased, the difference in ADL score between two
consecutive groups increased as well; i.e., the difference between the group with one chronic
condition and the group with two chronic conditions was 0.8 units, whereas the difference
between the group with three chronic conditions and the group with four chronic conditions
was almost two units (Table 2). The same picture was seen for the MHI.
Healthcare costs
Table 3 shows the association between multimorbidity and healthcare costs. Costs are pre-
sented in Euros (2015 exchange rate: 1$US = 0.92 €). Compared with those in the single-mor-
bidity group, the mean total health costs of the multimorbidity group was € 874 higher. The
Table 1. Associations between multimorbidity and health outcomes.
Health outcome ADL (Physical health) MHI (Mental health)
Model Part 1: Logistic Part 2: GLM OLS
OR 95% CI Exp(b��) 95% CI b�� 95% CI
Age 1.03 1.02 1.03 0.99 0.99 0.99 0.09 0.08 0.10
Female 1.40 1.23 1.58 1.16 1.06 1.28 -1.69 -2.04 -1.33
Education level� (reference: 1)
2 0.76 0.62 0.93 0.78 0.67 0.89 0.58 -0.04 1.20
3 0.64 0.52 0.77 0.67 0.59 0.77 1.68 1.11 2.25
4 0.58 0.46 0.73 0.61 0.51 0.72 2.21 1.57 2.85
5 0.39 0.29 0.53 0.70 0.55 0.89 2.09 1.34 2.84
Morbidity condition (reference: no morbidity)
Single morbidity 3.43 2.67 4.40 1.17 0.93 1.47 -1.72 -2.20 -1.25
Multimorbidity 13.17 10.55 16.44 1.43 1.17 1.76 -5.00 -5.44 -4.55
Constant 0.05 0.04 0.07 10.6 8.56 13.20 5.87 5.82 5.93
The number of participants is 7,741. The part 1 model of ADL is calculated with Eq (1); the part 2 model of ADL is calculated with Eq (2); the model of MHI is calculate
with Eq (4).
�Education level: 1 for primary school; 2 for Pre-vocational training; 3 for High school or vocational training; 4 for Higher education until Bachelor; 5 for Master/
doctorate.
��b: regression-coefficient
Abbreviations. ADL: activities of daily living, MHI: mental health inventory, OR: odds ratio, GLM: generalized linear model, OLS: ordinary least squares, CI:
confidential interval.
https://doi.org/10.1371/journal.pone.0243275.t001
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costs of GP care, pharmaceuticals, and hospital care were € 25, € 226, and € 355 higher in mul-
timorbidity patients than in single-morbidity patients.
Table 4 shows the impact of the number of chronic conditions on total healthcare costs.
One chronic condition increased the annual costs with € 600 whereas five or more conditions
increased the costs with € 3,949. Proportionally similar increases were seen for the categories
of costs.
Discussion
Our results demonstrated that multimorbidity has not only become more prevalent (0.4 mil-
lion additional people with multimorbidity) but also more severe in the Netherlands over the
past ten years. The percentage of people with three or more conditions increased and this
increase was highest in the category with five or more chronic conditions (0.8%-point). Hence,
the people with multimorbidity have more chronic conditions with increases their complexity
and further increases the challenges to the provision of integrated chronic care.
Compared with the latest reported Dutch study, our study showed a higher prevalence of
multimorbidity but a slower rate of increase over time. This previous study reported a preva-
lence estimate of 16.2% in 2011 [17], while our estimate was 24.4% in the same year. Preva-
lence estimates may vary as a result of a difference in population studied, list of chronic
Fig 3. Difference in ADL score compared to no morbidity across education levels. The number of participants is 7,741. The group without a chronic condition is
the reference group. �: A higher score indicates a worse ADL. The standard error bars were based on bootstrapping. ��Education level: 1 for primary school; 2 for Pre-
vocational training; 3 for High school or vocational training; 4 for Higher education until Bachelor; 5 for Master/doctorate.
https://doi.org/10.1371/journal.pone.0243275.g003
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conditions used, and source of data [56]. In contrast to our study, which was based on phar-
macy data, this previous study was based on regional GP-registrations. It reported an increase
in prevalence of multimorbidity of 0.4%-point per year, whereas our estimate showed 0.15%-
point increase per year. Our estimate might be lower because we estimated the increase on the
general population instead of regional GP-registrations.
Our study further showed that multimorbidity was associated with impaired physical and
mental health. More importantly, for each additional chronic condition the additional
impairment increased. The negative association between multimorbidity and physical health is
in line with previous studies [20, 57, 58], among which two studies based on Dutch data [6, 7].
However, these Dutch studies included people of 85 years or over who already have a worse
ADL score due to ageing alone. The negative association between multimorbidity and mental
health is also in line with previous studies [23, 24], although Fortin et al. reported a weaker
association [23]. The increasing impairment from each additional chronic disease further
stresses the need to adopt a person-centred holistic approach instead of a disease-specific
approach towards chronic disease management.
Our study clearly showed that multimorbidity disproportionally affected people with a
lower education level. The negative impact of multimorbidity on ADL was about three times
greater in those with the lowest education level than in those with the highest education level.
The negative impact of mental health was about two times greater, respectively. We found no
previous studies comparing the impact of multimorbidity between groups with different edu-
cation levels. This result highlights the need to specifically engage the lower educated patients
Fig 4. Difference in MHI score compared to no morbidity across education levels. The number of participants is 7,741. The group without a chronic condition is
the reference group. �: A lower score indicates a worse mental health. The standard error bars were based on bootstrapping. ��Education level: 1 for primary school; 2
for Pre-vocational training; 3 for High school or vocational training; 4 for Higher education until Bachelor; 5 for Master/doctorate.
https://doi.org/10.1371/journal.pone.0243275.g004
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in chronic disease management and provide targeted self-management support to the lower
educated patients.
Multimorbidity increased the total healthcare cost by € 874 as compared to people with a
single chronic condition. This was largely due to an increase in costs of medication (+€ 355)
Table 2. Associations between chronic conditions and health outcomes (N = 7,741).
Health outcome ADL MHI
Model Part 1: Logistic Part 2: GLM OLS
OR�� 95% CI Exp(b��) 95% CI b�� 95% CI
Age 1.02 1.02 1.03 0.99 0.98 0.99 0.10 0.09 0.12
Female 1.36 1.19 1.55 1.15 1.05 1.26 -1.59 -1.94 -1.24
Education level� (reference: 1)
2 0.76 0.61 0.95 0.77 0.67 0.89 0.54 -0.07 1.16
3 0.69 0.56 0.84 0.68 0.59 0.78 1.48 0.92 2.05
4 0.63 0.49 0.80 0.63 0.53 0.75 2.02 1.39 2.66
5 0.42 0.31 0.58 0.68 0.54 0.87 1.88 1.13 2.62
Number of chronic conditions (reference: no chronic condition)
1 3.53 2.75 4.53 1.18 0.95 1.48 -1.79 -2.26 -1.32
2 6.87 8.80 8.80 1.11 0.89 1.39 -3.41 -3.96 -2.86
3 11.03 14.33 14.33 1.12 0.94 1.47 -4.41 -5.07 -3.75
4 18.35 24.06 24.06 1.40 1.12 1.75 -5.88 -6.61 -5.14
5 or more 47.10 61.97 61.97 1.91 1.55 2.37 -8.65 -9.35 -7.96
Constant 0.05 0.06 0.06 10.54 8.51 13.04 5.89 5.84 5.95
The number of participants is 7,741. The part 1 model of ADL is calculated with Eq (1); the part 2 model of ADL is calculated with Eq (2); the model of MHI is calculate
with Eq (4).
�Education level: 1 for primary school; 2 for Pre-vocational training; 3 for High school or vocational training; 4 for Higher education until Bachelor; 5 for Master/
doctorate.
��OR: odds ratio, b: regression-coefficient
https://doi.org/10.1371/journal.pone.0243275.t002
Table 3. Associations between multimorbidity and healthcare costs (in Euro).
Cost types Total cost GP cost Pharmacy cost Hospital care cost
b�� 95% CI b�� 95% CI b�� 95% CI b�� 95% CI
Morbidity condition (reference: no chronic condition)
Single morbidity 613.0 607.7 618.4 21.8 21.7 21.9 140.3 139.6 141.1 316.0 312.1 320.0
Multimorbidity 1,487.0 1,479.9 1,494.2 47.4 47.2 47.5 365.9 364.9 366.9 661.3 656.0 666.6
Death� 3,685.0 3,670.3 3,699.7 199.0 198.8 199.3 -266.8 -269.0 -264.7 2,998.0 2,987.2 3,008.9
Year (reference: 2009)
2010 119.0 115.0 123.1 2.2 2.1 2.2 15.5 14.9 16.1 65.3 62.3 68.3
2011 236.7 232.6 240.7 15.9 15.8 15.9 26.2 25.7 26.8 140.8 137.8 143.7
2012 299.5 295.5 303.6 15.3 15.2 15.3 6.8 6.3 7.4 239.4 236.4 242.4
2013 513.9 509.8 517.9 22.4 22.3 22.4 6.1 5.5 6.7 351.3 348.3 354.3
2014 584.8 580.7 588.9 34.8 34.8 34.9 15.2 14.6 15.8 396.8 393.8 399.8
2015 729.4 725.3 733.5 37.2 37.1 37.3 31.3 30.7 31.9 372.1 369.1 375.2
Constant 1,303.9 1,300.6 1,307.3 101.9 101.9 102.0 169.3 168.8 169.8 707.2 704.7 709.7
�Death: 1 if the individual died in the given year; 0 if the person did not die in the given year
��b: coefficient
https://doi.org/10.1371/journal.pone.0243275.t003
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and costs of hospital care (+€ 226). There is no evidence of diminishing increases as the num-
ber of conditions increases. The association between multimorbidity and costs was previously
reported for Switzerland, Ireland, and the U.S. [32], and although they all found considerable
increases, the absolute increases are difficult to compare because of difference in healthcare
and insurance systems, prices, medical practice patterns and databases used. Previous Dutch
studies [59, 60] have only reported the association between multimorbidity and healthcare uti-
lization, but not costs.
Strength and limitations
A strength of our study was the use of comprehensive databases, yielding representative results
for the Netherlands. The Health Survey that was used to measure physical and mental health,
is send to a random sample of the Dutch adult population, and bias due to non-response is
reduced by weighting the data with respect to sex, age, ethnicity, marital status, geographic
characteristics, and survey season [61]. The pharmacy database that we used to estimate the
prevalence of multimorbidity covered over 90% of the population in the Netherlands. This
pharmacy database includes all medication prescribed by GP’s, to hospital outpatients and
patients in residential homes, but not medication prescribed during a hospital admission and
the over-the-counter medication. However, it is unlikely that this limitation has affected the
prevalence of multimorbidity because most chronic conditions require continuous pharmaco-
therapy with medicines that are only available on prescription from doctors and these pre-
scriptions are generally filled at local outpatient pharmacies. The health insurance database we
used included 98% of all declarations for services included in the basic benefit package. How-
ever, services covered by private health insurance and out-of-pocket expenditures were not
included. In 2015, they amounted to about 4.4% and 14.2% of total healthcare costs, respec-
tively [62]. Out-of-pocket payments mostly included the deductible of the basic health
Table 4. Associations between the number of chronic conditions and healthcare costs (in Euro).
Cost types Total cost GP cost Pharmacy cost Hospital care cost
b�� 95% CI b�� 95% CI b�� 95% CI b�� 95% CI
Number of chronic conditions (reference: no chronic condition)
1 600.6 595.3 606.0 21.5 21.4 21.5 137.2 136.4 137.9 311.5 307.6 315.5
2 1,202.5 1,195.0 1,210.0 39.3 39.2 39.5 291.7 290.6 292.8 559.3 553.8 564.8
3 1,869.9 1,860.4 1,879.3 58.7 58.6 58.9 470.1 468.7 471.5 792.9 785.9 799.9
4 2,701.0 2,689.1 2,713.0 80.5 80.3 80.7 675.9 674.2 677.7 1,110.7 1,101.9 1,119.6
5 or more 3,949.3 3,934.3 3,964.4 114.2 114.0 114.4 987.2 985.1 989.4 1,558.4 1,547.2 1,569.5
Death� 3,656.8 3,642.1 3,671.5 198.3 198.0 198.5 -273.9 -276.0 -271.7 2,987.7 2,976.8 2,998.5
Year (reference: 2009)
2010 108.4 104.4 112.4 1.9 1.8 2.0 12.8 12.2 13.4 61.4 58.5 64.4
2011 212.5 208.4 216.5 15.2 15.1 15.3 20.1 19.5 20.7 131.9 129.0 134.9
2012 268.0 264.0 272.1 14.4 14.4 14.5 -1.2 -1.8 -0.6 227.9 224.9 230.9
2013 478.8 474.7 482.9 21.4 21.3 21.5 -2.9 -3.4 -2.3 338.6 335.6 341.6
2014 541.3 537.2 545.3 33.7 33.6 33.7 4.1 3.5 4.7 381.0 377.9 384.0
2015 676.4 672.3 680.5 35.7 35.7 35.8 17.8 17.2 1.8 352.9 349.8 355.9
Constant 1,244.6 1,241.2 1,247.9 100.3 100.2 100.3 154.1 153.6 154.6 685.6 683.2 688.1
�Death: 1 if the person died in that given year; 0 if the person did not die in the given year
��b: coefficient
https://doi.org/10.1371/journal.pone.0243275.t004
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insurance (max €375 per person in 2015) and certain services like eyeglasses, contact lenses,
inlay soles and certain dental prostheses that not covered by basic health insurance. The latter
is generally not caused by or unique to certain chronic diseases. The deductible (the amount
paid out of pocket by the patient before a health insurer will pay any expenses) can be substan-
tial for patients with chronic diseases, but was not included because we only had data on costs
covered by the basic health insurance.
While many chronic conditions can be identified well based on pharmacy data, some are
more difficult. For example, a condition like chronic pain is challenging to identify since pain-
controlling medications are also accessible as over-the-counter medication, which is not
recorded in the pharmacy database. However, the stronger pain-controlling medications, such
as morphine, fentanyl and oxycodone, are only accessible with specialists’ prescription, which
are included on the pharmacy data. Additionally, the possibility of overestimating the preva-
lence of multimorbidity was reduced by applying the two-year continuously prescription crite-
ria in defining chronic conditions. However, the prescription of preventive medication at the
sub-clinical stage could lead to an overestimation. This especially pertains to hypertension-
control. To investigate the potential influence on the results, a sensitivity analysis that excluded
the first-line medications for hypertension-control (i.e. ATC code of diuretic agents) was per-
formed. This analysis shows a similar result. The prevalence of multimorbidity is 1.5 to 2%-
point lower than the original results and has a similar incremental trend.
A limitation of our study is that the Health Survey database only includes cross-sectional
data [42]. Consequently, the analysis of these data precluded conclusions on the causal associa-
tion between multimorbidity and physical and mental health outcomes [63]. On the other
hand, the impact of multimorbidity on the healthcare cost was estimated in panel data, which
does allow conclusions about causality since the unmeasured confounding factors and
reversed causality can be better addressed with panel data [64].
The possible non-response bias is inevitable for most questionnaire-based studies, and
there is no exception for the Health Survey database used in this study. However, this bias is
addressed by a weighting that CBS applies to ensure representation by age, gender, marital sta-
tus, province, household size, income and urbanity [61].
A further limitation is that we had to use ADL score was a proxy for physical health. The
questions in the ADL questionnaire are more applicable to people who are more severely ill,
which limits the assessment of subtle influences of chronic conditions on physical functioning
[65]. In future surveys a more comprehensive measure of physical health should be used.
Additionally, for future studies it would be interesting to analyse disease clusters to have
more insight in the effect of certain diseases combinations. That would, however, require a
larger sample size than in our current study.
Implications
The implications of these findings are that they raise awareness of the increasing problem of
multimorbidity, which calls for greater efforts in trying to limit the impact thereof on persons’
lives. These efforts should specifically target the more vulnerable groups such as those with a
lower education level. Person-centred integrated health and social care initiatives are expected
to contribute to the solution. However, surprisingly few of them offer additional or specific
services and support for lower educated groups. While recognizing it won’t be easy to reach
these groups, there is definitely a window of opportunity there. However, when more attention
is being paid to integrated care for people with a lower education level, the risk of stigmatizing
this group increases. Although there is an association between lower education level and worse
health, the majority of the population, also from the lower educated groups, is healthy. This
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calls for carefully targeting interventions to people within the lower educated group that need
support most.
Conclusion
This analysis of nationally representative data from the Netherlands has shown that multimor-
bidity is associated with seriously impaired physical and mental health and disproportionally
affects those with a lower education level. The impact of each additional chronic condition
seems to grow as the number of chronic conditions increases. Each additional chronic condi-
tion leads to a considerable increase in costs, especially for medication and hospital costs, and
there is no evidence of diminishing impact as the number of chronic conditions increases.
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